地拉罗司治疗效果怎么样呢？

People with chronic anemia such as thalassemia or sickle cell anemia often require regular red blood cell transfusions. Repeated infusions produce toxic and ultimately fatal iron accumulation in multiple tissues of the body as insoluble ferritin. This chronic iron overload occurs because the body cannot eliminate iron efficiently. Chronic iron overload is a serious symptom, and organ failure can occur due to the iron deposits produced. When the heart or liver is affected, the condition can be life-threatening. (deferasirox) is an oral iron chelator that was approved by the FDA in November 2005 for use in patients 2 years and older with chronic iron overload caused by blood transfusions. In December 2012, Deferasirox was approved by the European Commission for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT) syndrome who require chelation therapy due to contraindications or insufficiency of deferoxamine mesylate therapy. On January 23, 2013, the FDA approved a new indication for deferasirox for the treatment of chronic iron overload in patients aged 10 years and older with non-transfusion-dependent thalassemia (NTDT).

What is the therapeutic effect of deferasirox?

Clinical research is currently underway in China; phase II and III clinical trials and pharmacokinetic studies have shown that it has good safety and tolerability, can significantly reduce the iron load on the heart and liver, and is easily accepted by patients. At the same time, it also has pharmaceutical properties such as antifungal (such as Mucor growing in an iron-rich environment), anti-cell proliferation, anti-malaria, anti-oxidative stress damage, anti-cytotoxicity-induced apoptosis, etc.; it can be used for the treatment of secondary hemochromatosis, porphyria cutanea tarda and other diseases.

The common starting dose is 20 mg/(kg·d). If there is a large amount of blood transfusion and the iron increase is >0.5 mg/(kg·d) or the iron load before treatment is high, the recommended dose is 30 mg/(kg·d). If the iron increase is <0.3 mg/kg, 10-15 mg/kg/d is enough to control the disease. Administer on an empty stomach 30 minutes before meals and should be completely dissolved in water or apple or orange juice. Lower doses of deferasirox [5-10 mg/(kg·d)] can only be used in young patients with mild iron overload and few blood transfusions, or in elderly patients who have not received satisfactory results from chelation therapy in the past; patients using deferasirox 20 and 30 mg/(kg·d) need to carefully monitor body iron stores, because body iron levels may continue to rise in 50% and 10% of patients.